Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC jointly recommended amidst an investigation into adverse events.

ACIP maintained ... to the use of IXCHIQ ® in persons aged ≥65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious adverse events (SAEs ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Recommendations for the use of chikungunya vaccine were recently discussed at a meeting of the Advisory Committee on Immunization Practices.

The ACIP also voted to recommend a precaution related to the use of IXCHIQ ® in persons aged ≥65 years. This precaution is a response to an ongoing investigation by the CDC of six cases of serious ...

the ACIP voted to recommend a precaution related to the use of Ixchiq in patients aged 65 years and older due to an ongoing investigation by the CDC of 6 cases of serious adverse events ...

Valneva is committed to upholding the highest safety standards and has engaged proactively with health authorities in all territories where IXCHIQ ® is licensed to provide timely information about all ...